Therapeutic liver cell transplantation to treat murine PKU
Journal of Inherited Metabolic Disease · 2024
DOI: 10.1002/jimd.12802 ↗At a glance
Journal article in Journal of Inherited Metabolic Disease, 2024. Written by Melanie Willimann and 6 co-authors. Institution: Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Major MEDLINE topics: Phenylketonurias, Hepatocytes, Disease Models, Animal, Liver. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (original language)
For gene therapy of the liver, in vivo applications based on adeno‐associated virus are the most advanced vectors despite limitations, including low efficacy and episomal loss, potential integration and safety issues, and high production costs. Alternative vectors and/or delivery routes are of high interest. The regenerative ability of the liver bears the potential for ex vivo therapy using liver cell transplantation for disease correction if provided with a selective advantage to expand and replace the existing cell mass. Here we present such treatment of a mouse model of human phenylketonuria (PKU). Primary hepatocytes from wild‐type mice were gene modified in vitro (with a lentiviral vector) that carries a gene editing system (CRISPR) to inhibit Cypor . Cypor inactivation confers paracetamol (or acetaminophen) resistance to hepatocytes and thus a growth advantage to eliminate the pre‐existing liver cells upon grafting (via the spleen) and exposure to repeated treatment with paracetamol. Grafting Cypor ‐inactivated wild‐type hepatocytes into inbred young adult enu2 (PKU) mice, followed by selective expansion by paracetamol dosing, resulted in replacing up to 5% of cell mass, normalization of blood phenylalanine, and permanent correction of PKU. Hepatocyte transplantation offers thus an armamentarium of novel therapy options for genetic liver defects.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
- University of Zurich, Institute for Pharmacology and Toxicology, Zurich, Switzerland.
ORCID profiles: Gerald Schwank, Beat Thöny
Funding
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Cite
APA
Willimann, M., Grisch-Chan, H. M., Rimann, N., Rothgangl, T., Hruzova, M., Schwank, G., & Thöny, B. (2024). Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12802
Vancouver
Willimann M, Grisch-Chan HM, Rimann N, Rothgangl T, Hruzova M, Schwank G, et al. Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12802
BibTeX
@article{Willimann2024,
author = {Willimann, Melanie and Grisch-Chan, Hiu Man and Rimann, Nicole and Rothgangl, Tanja and Hruzova, Martina and Schwank, Gerald and Thöny, Beat},
title = {Therapeutic liver cell transplantation to treat murine PKU},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
doi = {10.1002/jimd.12802}
}
EUVIMED